https://www.businesswire.com/news/home/20180602005097/en/

CHICAGO--(BUSINESS WIRE)--Jun 2, 2018--NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on how targeting immune checkpoints and employing combinations has led to clinical benefit across a variety of tumor types during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“We are excited to share data on how profiling the tumor and associated microenvironment can help tailor rational combinations of immunotherapeutic strategies,” said Patrick Soon-Shiong, MD, founder of NantWorks. “This data is an important step in enhancing response rates through individualized immune checkpoints in PD-L1 expression, and we look forward to continued exploration and potential solutions for patients.”